Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment

Clinical and Experimental Ophthalmology

Volumn 36, Issue 8, 2008, Pages 748-755

  Fong, Kenneth C S ^a   Kirkpatrick, Nigel ^a   Mohamed, Quresh ^a   Johnston, Robert L ^a  

^a CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

Author keywords

Age related macular degeneration; Bevacizumab; Prognostic factors

Indexed keywords

BEVACIZUMAB; PLACEBO; RANIBIZUMAB; VERTEPORFIN;

AGED; BLEEDING; DISEASE COURSE; DRUG EFFICACY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; RETINA MACULA DEGENERATION; RETINA NEOVASCULARIZATION; RETROSPECTIVE STUDY; REVIEW; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; HUMANS; INJECTIONS; MACULAR DEGENERATION; MACULAR EDEMA; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 58149347420     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2008.01873.x     Document Type: Review

References (18)

1. Stone EM. A very effective treatment for neovascular macular degeneration. N Engl J Med 2006; 355: 1493-5.
2. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31.
3. Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-44.
4. Fung AE, Lalwani GA, Rosenfeld PJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-83.
5. Ferrara N, Hillan KJ, Gerber HP et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
6. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331-5.
7. Spaide RF, Laud K, Fine HF et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26: 383-90.
8. Avery RL, Pieramici DJ, Rabena MD et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-72, e5.
9. Emerson MV, Lauer AK, Flaxel CJ et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007; 27: 439-44.
10. Rich RM, Rosenfeld PJ, Puliafito CA et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006; 26: 495-511.
11. Bashshur ZF, Bazarbachi A, Schakal A et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 142: 1-9.
12. Goff MJ, Johnson RN, McDonald HR et al. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina 2007; 27: 432-8.
13. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: A short-term study. Am J Ophthalmol 2007; 143: 510-12.
14. Chan A, Duker JS. A standardized method for reporting changes in macular thickening using optical coherence tomography. Arch Ophthalmol 2005; 123: 939-43.
15. Bakri SJ, Snyder MR, Reid JM et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114: 855-9.
16. Bakri SJ, Snyder MR, Reid JM et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114: 2179-82.
17. Van de Moere A, Sandhu SS, Talks SJ. Correlation of optical coherence tomography and fundus fluorescein angiography following photodynamic therapy for choroidal neovascular membranes. Br J Ophthalmol 2006; 90: 304-6.
18. Sahni J, Stanga P, Wong D et al. Optical coherence tomography in photodynamic therapy for subfoveal choroidal neovascularisation secondary to age related macular degeneration: A cross sectional study. Br J Ophthalmol 2005; 89: 316-20.